Innate Pharma: Orphan Drug Designation in the European Union for IPH4102

Editor’s note: When a newly developed drug for a rare (“orphan”) disease seems particularly promising for patients, the European Commission may choose to grant it “orphan drug designation.” The designation removes certain barriers that might otherwise keep a drug company from being able to successfully develop and profit from the drug in Europe. A new drug called IPH4102 has just received an orphan drug designation for the treatment of cutaneous T-cell lymphoma (CTCL).

“Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, today announced that the European Commission has granted orphan drug designation to IPH4102 for the treatment of cutaneous T-cell lymphoma (CTCL).

“CTCL is a group of rare cutaneous lymphomas of T lymphocytes with poor prognosis and few therapeutic options at advanced stages. IPH4102 is a first-in-class cytotoxic anti-KIR3DL2 antibody, aiming at destroying CTCL cancer cells.
Hervé Brailly, Chief Executive Officer and co-founder of Innate Pharma, said: ‘This decision by the European Commission validates the IPH4102 approach in a disease with significant medical need and supports our strategy for a rapid clinical development’.

“Phase I trial with IPH4102 is expected to begin in 2015.”